Opthea is one ofBioshares top 6 stock tips for 2024.
While it’s there for all to see Bioshares notes thecompany's share price has been in decline since 2019, which it
attributes to the length of the Phase III trials and the subsequentlack of short-term stock drivers.
Yes, it will be mid 2025 based on current company guidancebefore we have phase III results so 6 years is indeed a long time betweendrinks and the phase IIb trial readout announcement in August 2019. Having saidthat I’d be prepared to bet if this was a US company the share price would befar north of where it is today given its advanced stage of development.
Bioshares also took note of Megan Baldwin being replacedby a US-based management team with a track record in M&A in ophthalmic therapeuticsand licensing deals. Then went on to surmise the recent investment interest followingthese changes is linked to possible expectations of commercial deals from thismanagement team, further indicating completion of phase III trial recruitmentmaybe an ideal time to secure regional licensing deals.
Opthea is one ofBioshares top 6 stock tips for 2024. While it’s...
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
78.0¢ |
Change
-0.010(1.27%) |
Mkt cap ! $960.2M | |||
| Open | High | Low | Value | Volume |
| 79.0¢ | 79.5¢ | 74.5¢ | $2.420M | 3.109M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 77.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 78.0¢ | 77447 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |